Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed May 3, 2024
- Accession no.
- 0001601830-24-000047
- Filed
- May 3, 2024
- Trade date
- May 1-2, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $810.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2024 | Class A Common Stock | GGiftDisposed | −25,000 | $0.00 | $0 | 913,524 | Direct | |
| May 1, 2024 | Class A Common Stock | SSaleDisposed | −50,000 | $7.73 | −$386,500 | 863,524 | Direct | |
| May 2, 2024 | Class A Common Stock | SSaleDisposed | −28,704 | $8.47 | −$243,122.88 | 834,820 | Direct | |
| May 2, 2024 | Class A Common Stock | CConversionAcquired | +21,296 | $0.00 | $0 | 856,116 | Direct | |
| May 2, 2024 | Class A Common Stock | SSaleDisposed | −21,296 | $8.47 | −$180,377.12 | 834,820 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2024 | Class A Common Stock | CConversionDisposed | −21,296 | $0.00 | $0 | 6,426,700 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.